Back

Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

28 August 2016 (12:45 - 12:50)
Organised by:
Congress Presentation Part of: SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management? Diabetes management ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
Challenging CV Risk in diabetes: ready for a new approach?
Professor J. Deanfield (London, GB)
Presentation thumbnail
SGLT-2 inhibitors in T2DM management: current position & future promise.
Professor S. Inzucchi (New Haven, US)
Presentation thumbnail
Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?
Professor J. McMurray (Glasgow, GB)
Presentation thumbnail
Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access the full session

Session thumbnail
SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

The Event

Event poster

ESC Congress 2016

28 August 2016 12:45 CET
You may be interested in
thumbnail
Congress Presentation
Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
27 August 2021
thumbnail
Webinar
Early initiation of SGLT-2 inhibitors after acute decompensated heart failure
26 October 2022
thumbnail
Congress Presentation
The evolution of Guidelines.
28 August 2022
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources